Hypoalphalipoproteinemia (HA) is a common finding in patients with premature coronary artery disease. To characterize the common familial forms of HA, we studied 102 families of probands with premature coronary artery disease; 40 probands (39.2%) had HA. Of these, 25 had at least one first-degree relative affected with HA; 11 had familial hypertriglyceridemia with HA (FTgHA); 10 had familial combined hyperlipidemia (FCH); and 4 had familial HA (FHA) with no other lipoprotein abnormalities. In the remaining 15 families, no lipoprotein abnormalities were observed in first-degree relatives. We measured apolipoprotein (apo) A-I, B, C-IH, and E levels as well as lipoprotein particle (Lp) levels of LpA-I (containing apoA-I only), LpA-I:A-II (containing both apoA-I and A-II), LpB:E, and LpB:C-III. Compared with a reference group of healthy men (n = 103) and women (n = 106), probands with familial forms of HA had lower high-density lipoprotein cholesterol levels by selection criteria. Triglyceride levels were higher in FTgHA and FCH probands than in the reference group or FHA subjects. Despite selection of FTgHA and FCH by low-density lipoprotein (LDL) cholesterol, the latter was not significantly different between the three groups and the reference group. ApoA-I levels were decreased in FCH, FHA, and FTgHA probands, and LpA-I and LpA-I:A-II were lower in FHA and FTgHA probands. ApoB levels were significantly higher in all familial HA groups compared with the reference group, being highest in FCH individuals, but not significantly higher between FCH, FTgHA, or FHA probands. LpB:E levels were higher in the FCH and FTgHA groups than in the reference group. There were no significant differences between groups for apoE, apoC-III, and LpB:C-III. LDL particle size was smaller in all three forms of FHA, which, in combination with higher apoB levels, reflects an increased number of smaller, denser LDL particles. Affected children had, on average, higher apoB and LpB:E levels than nonaflected siblings. Our data suggest that common forms of FHA in subjects with coronary artery disease represent a spectrum of overlapping disorders characterized by an increase in apoB-containing lipoproteins, especially LpB:E particles, and smaller, denser LDL particles. When using appropriate age-and gender-adjusted cutpoints, approximately half the offspring (in young adulthood) appeared to be affected. 
H ypoalphalipoproteinemia (HA) defined as a high-density lipoprotein cholesterol (HDL-C) level below the 10th percentile for age-and gender-matched subjects, is seen frequently in patients with premature coronary artery disease (CAD). We have previously reported that 36% of men with angiographically documented CAD below the age of 60 years have HA. 1 Familial hypoalphalipoproteinemia (FHA), defined for the purpose of this study as an HDL-C level below the 10th percentile of age and gender norms in the proband and at least one first-degree relative irrespective of other lipoprotein cholesterol or apolipoprotein levels, may represent a genetic lipoprotein abnormality that, given the proper environmental circumstances and other cardiovascular risk factors (male gender, smoking, diet, hypertension, and diabetes), predisposes affected individuals to develop CAD. There is some controversy whether certain forms of FHA predispose to premature CAD. 2 We have previously determined the prevalence of familial lipoprotein abnormalities in 102 families of patients with angiographically documented premature coronary atherosclerosis. We have observed that a familial lipoprotein disorder was present in 53.9% of the probands, 3 with familial combined hyperlipoproteinemia (FCH) (13.7%), familial hypertriglyceridemia with hypoalphalipoproteinemia (FTgHA) (15.7%), and isolated FHA (low HDL alone) (4%) being the disorders associated with a low HDL-C segregating within families.
The biochemical characterization of familial lipoprotein disorders often centers on the lipid or apolipoprotein composition of the various lipoprotein classes involved. A novel technique of lipoprotein particle measurement based on apolipoprotein composition has allowed new insights into the physiological properties of various subclasses of lipoproteins. The predominant lipoproteins within plasma contain apolipoprotein (apo) A-I or apoB. 4 In a study of men with coronary disease, we have shown that apoA-I-containing lipoproteins LpA-I (lipoproteins containing only apoA-I) and LpA-I: A-II (containing both apoA-I and apoA-II) are reduced, whereas LpB:E (lipoproteins containing apoB and apoE) but not LpB:C-III (lipoproteins containing apoB and apoC-III) are increased compared with a control group free of clinical manifestations of CAD. 5 The purpose of this study was to determine the prevalence of FHA in probands (men and women) with premature CAD; to characterize, by using specific lipoprotein particle measurement, the common forms of FHA; and to determine the interrelations between the various common forms of HA.
Methods

Family Studies
Patients were selected on the basis of having angiographically documented CAD before the age of 60 years. Family studies were performed on the basis of availability of first-degree relatives and willingness to participate, irrespective of lipid or lipoprotein levels or family history of coronary disease. The characteristics of probands and the methodology used in the family studies have been described. 3 All patients underwent elective cardiac catheterization and coronary angiography for the diagnosis of CAD at the New England Medical Center in Boston, Mass. The referral base of the New England Medical Center Hospital includes the Boston area as well as eastern Massachusetts. Patients with acute myocardial infarction, surgery, or trauma in the preceding 6 weeks before admission were excluded, as were those on lipid-lowering medications. Information on other risk factors including hypertension (defined as a history of blood pressure > 150/95 mm Hg, treated or untreated), diabetes (history of diabetes or treatment with oral hypoglycemics or insulin), and smoking (10 or more cigarettes per day in the year preceding the procedure) as well as medications was noted by direct interview and review of the patient's medical chart. The degree of CAD was determined by two independent cardiologists unaware of the patient's inclusion in the study. The presence of CAD, defined as >50% stenosis of a major coronary artery, was identified on multiple projections (>75% cross-sectional area stenosis). Patients with minimal disease (<50% stenosis) or with normal angiograms (n=25) were rejected from the study. From a group of 259 (83% men and 17% women) patients, 102 nuclear families were sampled, including 96 genetically unrelated spouses and 382 first-degree relatives. 3 The definition and cutpoints used for FCH, FTgHA, and FHA are described elsewhere. 3 
Reference Group
A reference group of 103 men and 106 women was randomly selected from the Framingham Offspring Study (third examination cycle). Age was 49±11 (mean±SD) years in men and 49±10 years in women. None of the control subjects had clinical or electrocardiographic manifestations of cardiovascular disease. There were no significant differences in the 209 control subjects selected and the rest of the group for age or plasma levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), HDL-C, apoA-I, or apoB. Therefore, with respect to conventional lipoprotein cholesterol and apoA-I and apoB, our reference group appears to be representative of the larger Framingham control group. 5 
Lipid and Lipoprotein Cholesterol Measurements
Plasma total cholesterol, triglyceride, and HDL-C levels were determined by using enzymatic techniques; HDL-C was determined after dextran-Mg 2+ precipitation.
1 LDL-C was calculated according to the method of Friedewald et al 6 unless the triglyceride concentration was >400 mg/dL, in which case cholesterol was measured in the d> 1.006 infranate after ultracentrifugation; LDL-C was then calculated as infranate cholesterol minus HDL-C. Multiple aliquots of plasma were frozen at -80°C for subsequent analysis of apolipoproteins.
ApoA-I and apoB levels were measured by noncompetitive enzyme-linked immunosorbent assay (ELISA). Normal ranges for apoA-I and apoB were determined in over 3541 participants (men and women) of the Framingham Offspring Study. 7 -8 LDL particle size was determined on gradient gel electrophoresis by using 2% to 16% nondenaturing polyacrylamide gels (Pharmacia, Piscataway, NJ) as described. 9 A higher particle size indicates a smaller, denser LDL particle. Because more than one LDL size band can be identified with this technique, a "weighted" LDL score was determined by densitometric scan of the gel by multiplying each band by its relative peak area to produce an LDL score. 9 
Lipoprotein Particle Determinations
Lp:A-I was determined by differential electroimmunoassay 4 -510 ; LpB:C-III, LpB:E, and LpA-I:A-II were quantified by using a two-site ELISA. 4510 The ELISA for LpB:C-III and LpB:E used 96-well plates (Costar, Sercolustar) precoated with purified antibodies to apoC-III or apoE. Plasma samples and standards were added, and the reaction was incubated at 37°C for 2 hours. After washings, the plates were incubated with peroxidase-labeled antibody to apoB and were then incubated for 2 hours at 37°C. The reaction was stopped by the addition of 1 mol/L HC1, and absorbance was read at 492 nm. 4 
Statistical Analysis
Data were stored on a VAX 11/780 computer (Digital Equipment Corp, Maynard, Mass) on the RS/1 database (BBN Software, Cambridge, Mass) and were analyzed by using SAS (Statistical Analysis Software, Cary, NC). Parametric data were analyzed by t tests and nonparametric data were analyzed by Mann-Whitney U test. Differences in frequencies of a discrete trait were analyzed by x 2 analysis.
Results From the group of 102 families, 40 probands had an HDL-C <10th percentile for age and gender. Of those, 15 did not show family segregation (ie, at least one affected first-degree relative with this abnormality). These families were considered to have a "spurious" form of HA and were excluded. The 25 remaining probands form the basis of this study. The clinical characteristics of the 25 probands (4 women and 21 men) are shown in Table 1 . One proband (No. 189) had tendinous xanthomas, xanthelasmas, and corneal arcus. He had a family history of premature CAD and severe hypercholesterolemia. Genetic analysis showed that the patient was heterozygous for the French Canadian mutation of the LDL receptor (>10-kb deletion of the 5' end of the gene) 11 that cosegregated with LDL-C levels >95th percentile. Study of his family revealed the presence of FTgHA independent of the LDL receptor defect. Although this patient is included in Table 1 , his lipoprotein data were not included in the final analysis because his very high levels of apoB-containing particles would confound the analysis. One first-degree relative of the proband with familial hypercholesterolemia was excluded from the family analysis.
Probands
The mean age of the probands was not significantly different from that of the reference groups (Table 1) . Lipid and lipoprotein cholesterol levels and the presence or absence of hypertension, diabetes mellitus, and the use of /3-adrenergic-blocking drugs (/3-blockers) are Apo indicates apolipoprotein; LDL, low-density lipoprotein; LDL size, LDL particle size; and ND, not determined. See "Discussion" for comments on LDL particle size and use of /3-adrenergic-blocking agents.
P<.01 compared with the reference group. tProband No. 189, who was heterozygous for familial hypercholesterolemia, was excludedshown in Table 1 . ApoA-I and apoB levels and weighted LDL particle size in the probands are shown in Table 2 . By selection criteria (see "Methods"), probands with FCH had higher total cholesterol, LDL-C, and triglyceride levels. Probands with familial hypertriglyceridemia with low HDL had higher triglyceride levels and those with isolated HA had low HDL-C. All probands by selection had an HDL-C level <10th percentile for age and gender. A control group of 103 men and 106 women was included solely for the purpose of comparing lipid, lipoprotein cholesterol, apolipoprotein, and lipoprotein particle levels with the probands. ApoB-containing lipoprotein particle measurements in the probands and in the reference group are shown in Fig 1 for apoB, Fig 2 for LpB:C-III, and Fig 3 for LpB:E levels. The mean level of apoB was significantly higher in all forms of FHA than in control subjects (P<.05), being highest in the FCH probands. No significant differences in apoB levels were observed between the various forms of FHA (Table 2 and Fig 1) . LpB:C-III FTgHA (10.8+4.7 mg/dL) or FHA individuals (9.0+3.2 mg/dL) (Fig 2) . In contrast, LpB:E particle levels were significantly higher in FCH (57.3 + 3.3 mg/dL; P<.01), FTgHA (41.7±25.2 mg/dL; /><.O1), and FHA (40.0+16.0 mg/dL; P<.01) probands compared with reference men (23.5±18.4 mg/dL). Differences in LpB:E levels between FCH and FTgHA or FHA subjects did not reach statistical significance (Fig 3) .
ApoA-I-containing lipoprotein particle levels are shown in Figs 4, 5, and 6. ApoA-I levels were significantly lower in FCH (114±22 mg/dL), FTgHA (96±21 mg/dL), and FHA (94 ±6 mg/dL) probands than in reference men (143±38 mg/dL; all P<.Ol) (Fig 4) . There were no significant differences in apoA-I levels between the different forms of FHA. LpA-I levels were lower in FTgHA (31.1 ±6.7 mg/dL) and isolated FHA (27 ±6.7 mg/dL) probands but not in FCH probands (43.7± 15.0 mg/dL) compared with reference men (46.1 ±14.8 mg/dL; P<.01 for FTgHA and FHA probands) (Fig 5) . Compared with the male reference group (90.5±20 mg/dL), LpA-I:A-II levels were reduced in FCH (73.7±12.6 mg/dL; P<.05), FTgHA (58.5±20.2 mg/dL; P<.01), and FHA (57.0±7.9 mg/dL; P<.01) probands (Fig 6) . Neither LpA-I nor LpA-I:A-II levels were significantly different between the three groups of patients with FHA syndromes.
LDL particle size, as determined by nondenaturing gradient gel electrophoresis, was higher (indicating a smaller, denser particle) in all forms of FHA (Table 2 ). Subjects with FCH had an LDL particle size of 5.00±1.23 (mean±SD); those with FTgHA, 4.23±1.11; and those with FHA, 4.35±0.10. In five subjects, LDL particle size was not determined. For reference men, LDL particle size was 3.43±1.12; for women, it was 2.47+0.98.
No trend clearly separated the 15 probands defined as having a spurious form of HA from the ones characterized with FHA. In this group of 2 women and 13 men, 5 were taking /3-adrenergic-blocking drugs, 9 had a history of smoking, 5 were hypertensive, and 2 were diabetic. Body mass index was 27.9±4.4. Mean HDL-C was 27.4 mg/dL. There were 47 first-degree relatives (3.13 per proband compared with 4.0 for the 25 probands with FHA).
Relatives
First-degree relatives were then analyzed. Two parents, 14 siblings, and 84 children were available for analysis (45 males and 55 females). There was an average of 4 first-degree relatives per proband (similar to the 3.75 that we have previously reported
3 ). Table 3 shows the distribution between affected and nonaffected relatives. Of those 100 first-degree relatives, one carried a defect at the LDL receptor gene locus and was excluded. In all, 99 first-degree relatives were included in the present study. Table 3 documents that approximately half of the relatives were affected by the three forms of FHA. The number of affected women (31/54, 57%) was slightly higher than men (18/45, 40%; P<.05). Furthermore, both men and women with a mean age of 26 or 28 years, respectively, were affected (the inclusion or exclusion of family No. 189 in Table 2 did not alter the results).
Lipid and lipoprotein cholesterol levels in affected and nonaffected relatives, separated by gender, are shown in Table 4 . The number of relatives in each group often did not allow meaningful statistical comparison. In the three forms of FHA described here, affected relatives had lower HDL-C levels than nonaffected individuals. In addition, triglyceride and LDL-C levels tended to be higher in the FCH-and FTgHA-affected relatives than in the FHA relatives. Similarly, triglyceride levels tended to be higher in the FCH and FTgHA relatives than in nonaffected individuals.
ApoA-I and apoB levels are shown in Table 5 . FCH and FTgHA individuals tended to have higher apoB levels than nonaffected individuals (only 1 man and 4 women affected in the FHA families made comparison difficult). ApoA-I tended to be lower in affected men in all three familial syndromes. Limited data were available on LDL particle size in children. However, affected relatives with FCH or FTgHA had, on average, smaller LDL particle size than nonaffected relatives, in both men and women. In FHA relatives, too few relatives had *P<.05 women more frequent than men.
LDL particle size determination performed to allow comparison. LpA-I, LpA-I:A-II, LpB:E, and LpB:C-III levels in affected and nonaffected relatives are shown in Table 6 . LpB:E tended to be higher in the affected individuals (especially men) in the three familial groups. In contrast, no such elevation was observed for LpB:C-III in FCH, FTgHA, and FHA relatives. In FTgHA relatives, LpA-I:A-II appeared to be lower in affected relatives and LpA-I was lower in affected women.
Discussion
The data presented here suggest that the common forms of FHA encountered in patients with CAD represent a broad spectrum of overlapping disorders characterized by decreased plasma levels of LpA-I and LpA-I:A-II, increased plasma levels of apoB-containing particles, including LpB:E particles, and by smaller, denser LDL particles. Considering the elevation in total plasma apoB, this would reflect an increased number of smaller, denser LDL particles. This syndrome, described as hyperapobetalipoproteinemia (hyperapoB), 12 ' 13 or by LDL pattern B 14 is commonly encountered in patients with premature CAD.
In our view, many of the families presented in this study have FCH or hyperapoB, 12 and if more firstdegree relatives had been available for analysis then the varying phenotypes would have been encountered. If this is indeed the case, FCH (or familial hyperapoB) would account for the majority of genetic lipoprotein disorders encountered in premature CAD, with most cases being associated with low HDL-C. 3 Despite the selection criteria used in this study and the arbitrary cutpoints, a similar pattern of increased apoB-contain- ing lipoprotein particles and decreased apoA-I-containing lipoprotein particles was found in our patients with HA.
The pathogenesis of increased plasma apoB is not fully understood. The current data suggest that hepatic oversecretion of apoB underlies most cases of FCH (or hyperapoB). 15 - 21 The underlying metabolic defects in FCH are now better understood. There is enough evidence to suggest that it shares many biochemical and physiological features of familial hyperapoB so that the two can be considered part of the same syndrome, characterized by increased hepatic oversecretion of apoB-containing particles. There are currently at least four distinct genetic or metabolic disorders associated with FCH/hyperapoB: reduced binding of acylationstimulating protein 22 ; heterozygous lipoprotein lipase deficiency 23 ; genetic variability at the apoA-I-C-III-A-IV gene locus (an Xmn I polymorphism 5' of the apoA-I-C-III-A-IV gene) 24 ; and a region on chromosome 19 at, or near, the LDL receptor gene locus. 25 The genetics of FCH or hyperapoB are not fully understood. In part, this is due to the difficulty in the unambiguous assignment of the FCH phenotype. By convention, subjects are considered affected if they exceed an arbitrary cutpoint of a lipoprotein or apolipoprotein level. Given the gaussian distribution of lipoprotein cholesterol and apoB levels, this amounts to dichotomizing a continuous variable. Age of expression and gender differences also contribute to the difficulty in assigning a phenotype. Despite these caveats, approximately half of the first-degree relatives exceeded our cutpoints defining abnormality, with no significant gender differences. It is noteworthy that the mean age of relatives (excluding parents and siblings) was 24 through 28 years (Table 2) . In this respect, our data are in keeping with earlier descriptions of FCH. 2628 In addition, apoB levels appear, at least in part, to be heritable, 329 with a bimodal distribution in relatives of subjects with FCH. 30 Rare defects of the apoA-I-C-III-A-IV gene complex on chromosome Ilq23 are associated with severe HA. 31 Single amino acid substitutions of apoA-I are usually not associated with abnormal levels of apoA-I, with the exception of apoA-I Milano .
2 Although HDL-C levels are reduced in subjects with apoA-I M ,, ano , the condition is not thought to be associated with CAD.
2 Defects involving major rearrangement of the apoA-I gene (or a portion of chromosome Ilq23) are exceedingly rare and do not contribute to the prevalence of HA in patients with CAD. 31 Common forms of FHA do not appear to be associated, in some studies, with the apoB gene or the apoA-I-C-III-A-IV gene complex by haplotype analysis. 3234 It is likely that under specific environmental influences multiple genetic abnormalities contribute to the expression of hyperapoB or FCH. The decrease in HDL-C levels and HDL particle number (reflected in decreases in both core constituents and apolipoproteins) observed in the probands and their relatives in this study may be secondary to an increased number of apoB-containing lipoproteins.
Of interest, LDL particle size measurement revealed that patients with the three forms of FHA have smaller, LpA-l indicates lipoproteins containing apolipoprotein (apo) A-l only; LpA-l:A-ll, lipoproteins containing both apoA-l and apo A-l I; LpB:C-lll, lipoproteins containing both apoB and apoC-lll; LpB:E, lipoproteins containing both apoB and apoE; and subjects tested, number of subjects in whom the lipoprotein measurement was performed.
denser LDL particles. The use of /3-adrenergic-blocking drugs (/3-blockers) is associated with smaller LDL particles 35 ; 11 of our 25 probands were on such medication (Table 1) , whereas by selection criteria, none of the reference subjects were on such medication. Based on our previous work, 35 we can estimate the effects of /3-blockers on LDL particle size. Correcting for the use of such medication in the probands, subjects with FCH have an LDL size of 4.45±1.30 (mean±SD); those with FTgHA, 3.77±0.86; and those with FHA, 4.02±0.62. The reference group had an LDL particle size of 3.43±1.12 for men and 2.47±0.98 for women. When adjusted for /3-blocker use, LDL particle size was significantly smaller in all forms of FHA (/"<.O5) compared with healthy individuals.
The association of familial dyslipidemia, hypertension, abdominal obesity, and insulin resistance 3639 suggests that the pathogenesis of combined lipoprotein disorders encountered in the present study is far more complex than previously thought. Several of our patients had hypertension (n=8) or diabetes mellitus (n=2). We did not perform glucose tolerance tests, nor did we measure insulin levels after a glucose load. In the evaluation of the genetic and molecular basis of the syndromes associated with elevated hepatic apoB secretion, the association with hypertension, obesity, and insulin resistance must be taken into account.
The treatment of patients with decreased HDL-C, especially in the secondary prevention of cardiovascular disease, is a matter of controversy. General principles of treatment include cessation of smoking, dietary intervention, and physical exercise. If decreased HDL-C is associated with elevated triglycerides and/or LDL-C, treatment should be aimed at decreasing the number of apoB-containing particles and to increase HDL-C levels. The drugs of first choice include niacin, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, and fibric acid derivatives. The Familial Atherosclerosis Treatment Study, 40 in which patients with CAD and elevated apoB levels were randomized to conventional diet therapy or to one of two aggressive regimens designed to reduce LDL-C (with lovastatin and colestipol) or to reduce LDL-C and increase HDL-C (with niacin and colestipol), has documented that reduction of apoB-containing particles and increases in HDL-C were beneficial in terms of decreasing angiographic progression of coronary atherosclerosis and cardiovascular events.
